Publication | Closed Access

Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer

Cancer ImmunosurveillanceMedicineImmunologyTumor ImmunityPd-1 InhibitorsImmunoeditingBronchial NeoplasmImmune Checkpoint InhibitorCancer TreatmentLung CancerImmunotherapyOncologyCell BiologyTumor MicroenvironmentLow-dose Carboplatin Reprograms